(0.10%) 5 522.25 points
(0.14%) 39 898 points
(0.19%) 19 789 points
(-0.06%) $81.58
(0.57%) $2.83
(-0.23%) $2 339.00
(0.17%) $29.58
(0.45%) $1 006.30
(0.05%) $0.932
(-0.02%) $10.53
(0.02%) $0.788
(-0.85%) $87.25
-1.35% $ 5.10
Live Chart Being Loaded With Signals
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas...
Stats | |
---|---|
Dzisiejszy wolumen | 2.40M |
Średni wolumen | 2.31M |
Kapitalizacja rynkowa | 607.33M |
EPS | $-0.290 ( Q1 | 2024-05-13 ) |
Następna data zysków | ( $-0.230 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.10 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0140 (0.27%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-13 | Sebelius Kathleen | Buy | 50 000 | Stock Options (right to buy) |
2024-06-14 | Sebelius Kathleen | Buy | 39 389 | Common Stock |
2024-06-14 | Sebelius Kathleen | Sell | 39 389 | Stock Options (right to buy) |
2024-06-13 | Windham-bannister Susan Richards | Buy | 50 000 | Stock Options (right to buy) |
2024-06-13 | Wallace Max N. | Buy | 50 000 | Stock Options (right to buy) |
INSIDER POWER |
---|
-69.62 |
Last 98 transactions |
Buy: 4 304 857 | Sell: 32 030 639 |
Wolumen Korelacja
Humacyte, Inc. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Humacyte, Inc. Korelacja - Waluta/Towar
Humacyte, Inc. Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-7.72M (0.00 %) |
EPS: | $-1.070 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-7.72M (0.00 %) |
EPS: | $-1.070 |
FY | 2022 |
Przychody: | $1.57M |
Zysk brutto: | $-6.69M (-427.48 %) |
EPS: | $0.620 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Humacyte, Inc.
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej